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Heterozygous missense mutations in the triggering receptor expressed on myeloid
cells 2 (TREM2) have been reported to significantly increase the risk of developing
Alzheimer’s disease (AD). Since TREM2 is specifically expressed by microglia in the
brain, we hypothesized that soluble TREM2 (sTREM2) levels may increase together
with in vivo biomarkers of microglial activity and amyloidosis in an AD mouse model
as assessed by small animal positron-emission-tomography (µPET). In this cross-
sectional study, we examined a strong amyloid mouse model (PS2APP) of four age
groups by µPET with [18F]-GE180 (glial activation) and [18F]-florbetaben (amyloidosis),
followed by measurement of sTREM2 levels and amyloid levels in the brain. Pathology
affected brain regions were compared between tracers (dice similarity coefficients)
and pseudo-longitudinally. µPET results of both tracers were correlated with terminal
TREM2 levels. The brain sTREM2 levels strongly increased with age of PS2APP mice
(5 vs. 16 months: +211%, p < 0.001), and correlated highly with µPET signals of
microglial activity (R = 0.89, p < 0.001) and amyloidosis (R = 0.92, p < 0.001).
Dual µPET enabled regional mapping of glial activation and amyloidosis in the mouse
brain, which progressed concertedly leading to a high overlap in aged PS2APP mice
(dice similarity 67%). Together, these results substantiate the use of in vivo µPET
measurements in conjunction with post mortem sTREM2 in future anti-inflammatory
treatment trials. Taking human data into account sTREM2 may increase during active
amyloid deposition.
Keywords: Alzheimer’s disease, neuroinflammation, TREM2, amyloid-PET, TSPO-PET
Abbreviations: AD, Alzheimer’s disease; APP, amyloid precursor protein; ANOVA, Univariate analysis of variance; Aβ,
β-amyloid peptide; BCA, bicinchoninic acid; CSF, cerebrospinal fluid; PS, presenilin; SPM, statistical parametric mapping;
sTREM2, soluble triggering receptor expressed on myeloid cells 2; SUVR, standard-uptake-value-ratios; TBS, Tris-buffered
saline; TREM2, triggering receptor expressed on myeloid cells 2; TSPO, 18-kDA translocator protein; TXrigid, rigid-body
transformation; TXBN, non-linear brain normalization; VOI, volume-of-interest.
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INTRODUCTION
Alzheimer’s disease (AD), the most common cause of dementia,
has an exponentially increasing incidence as a function of
age, and is thus imposing an ever more onerous burden
on health care in countries with aging populations (Ziegler-
Graham et al., 2008). This motivates a worldwide effort to find
new biomarkers predicting future cognitive decline in patients
with suspicion of early AD, and likewise for use as outcome
measures in clinical trials of innovative disease-modifying
agents (Weiner et al., 2012). While the classical hallmarks of
AD pathology are the accumulation of extracellular amyloid
plaques and intracellular neurofibrillary tangles (Duyckaerts
et al., 2009), there is increasing evidence that microglia and
neuroinflammation is related directly to the pathogenesis of the
disease (Heneka et al., 2015). Many aspects of the amyloid and
tau pathologies are closely recapitulated in transgenic rodent
models for AD (Teipel et al., 2011; Hall and Roberson, 2012),
which can be monitored by small animal positron-emission-
tomography (µPET) using radioligands targeting the proteins
accumulating in AD (Virdee et al., 2012; Zimmer et al., 2014).
In particular, imaging of the accumulation of the β-amyloid
peptide (Aβ) has been proven useful for the in vivo detection
of AD pathology in patients (Price et al., 2005), and this class
of tracers are currently used for Aβ imaging in transgenic mice
(Manook et al., 2012; Rominger et al., 2013). The availability of
different in vivo tracers (i.e., for amyloid, glial activation) may
allow us to study the sequence of events that occur in thesemouse
models.
Microglia cells are the resident macrophages of the brain.
Two independent studies recently identified rare heterozygous
variants in the triggering receptor expressed on myeloid cells 2
(TREM2), which increase the risk for late onset AD significantly
(Guerreiro et al., 2013; Jonsson et al., 2013). TREM2 undergoes
regulated intramembrane proteolysis (Wunderlich et al., 2013;
Kleinberger et al., 2014) releasing the soluble TREM2 (sTREM2)
which can be readily detected in biological fluids, such as
the cerebrospinal fluid (CSF; Piccio et al., 2008; Kleinberger
et al., 2014). Recent studies indicate a dynamic increase in CSF
sTREM2 levels across the continuum of AD, with a significant
increase already present at the early symptomatic stages (Suárez-
Calvet et al., 2016b). Interestingly, sTREM2 levels show a strong
correlation with markers of neuronal degeneration, probably
due to a change of the glia reactivity in response to neuronal
injury (Heslegrave et al., 2016; Piccio et al., 2016; Suárez-
Calvet et al., 2016b). It follows that sTREM2 levels might serve
as a potential biomarker for microglial activation during AD
pathogenesis.
Activated microglia express high levels of the 18-kDA
translocator protein (TSPO), which is known as a target
detectable with a variety of PET ligands, among which [18F]-
GE180 has excellent properties for quantitation of TSPO
(Dickens et al., 2014; Wickstrøm et al., 2014). Dual tracer
µPET imaging of Aβ and TSPO was recently established in
the transgenic PS2APP mouse model (Brendel et al., 2016),
a strain that is known for a strong inflammatory component
besides the remarkable age-dependent amyloidosis (Richards
et al., 2003; Ozmen et al., 2009); the dual tracer approach
revealed associations of neuroinflammation and amyloidosis.
TSPO µPET with [18F]-GE180 as well successfully detected
age-dependent neuroinflammation in APP/PS1dE9, another AD
mouse model, and to a lesser extent in wild-type (WT) mice
(Liu et al., 2015) and [11C]PBR28 showed increased uptake in
5XFADmice compared to age-matched WTmice (Mirzaei et al.,
2016).
Given this background, the aims of the present cross-sectional
multitracer study were: (1) to study the age-dependent changes
in sTREM2 levels and µPET signals for the second generation
TSPO tracer [18F]-GE180 together with that of the Aβ tracer
[18F]-florbetaben in PS2APP and WT mice; (2) to evaluate
the association of sTREM2 levels in the brain with the µPET
signals and Aβ levels; and (3) to define the spatial and temporal
relationships of TSPO activity and amyloidosis during aging of
these mice.
MATERIALS AND METHODS
Radiochemistry
Radiosynthesis of [18F]-GE180 was performed as previously
described (Wickstrøm et al., 2014), with slight modifications
(Brendel et al., 2016), a procedure yielding radiochemical purity
exceeding 98%, and specific activity of 1400 ± 500 GBq/µmol
at end of synthesis. Radiosynthesis of [18F]-florbetaben was
performed as previously described (Rominger et al., 2013),
a procedure yielding radiochemical purity exceeding 98%,
and specific activity of 80 ± 20 GBq/µmol at the end of
synthesis.
Animals
All experiments were carried out in compliance with the National
Guidelines for Animal Protection, Germany with the approval
of the regional Animal care committee of the Government of
Oberbayern (Regierung Oberbayern), and were overseen by a
veterinarian. Female animals were housed in a temperature-
and humidity-controlled environment with a 12-h light–dark
cycle, with free access to food (Ssniff, Soest, Germany) and
water.
The transgenic B6.PS2APP (line B6.152H) is homozygous
for both, the human presenilin (PS) 2, N141I mutation and
the human amyloid precursor protein (APP) K670N, M671L
mutation. The APP and PS2 transgenes are driven by mouse
Thy-1 and mouse prion promoters, respectively. This line
had been created by co-injection of both transgenes into
C57Bl/6 zygotes (Richards et al., 2003). Homozygous B6.PS2APP
mice show first appearance of plaques in the cerebral cortex and
hippocampus at 5–6 months of age (Ozmen et al., 2009).
Study Design
µPET with [18F]-GE180 and [18F]-florbetaben emission
recordings (maximum 10 days apart) were obtained cross-
sectionally in equal-sized groups (N = 8) of PS2APP and WT
mice aged 5, 8, 13, and 16 months (±0.5 months). Group-size
calculations were planned based on the assumption of a
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type I error α = 0.05, giving a power of 0.8, and with the
possibility of substitution in case of dropouts. Within 1 week
after completion of the final PET session, PS2APP mice were
perfused with PBS while deeply anesthetized, and brains
were removed for biochemical and immunohistochemical
analyses. In case of dropouts (N = 7) additional age-matched
mice were substituted for the dual µPET ([18F]-GE180 and
[18F]-florbetaben) arm of the study, as equal group sizes are
necessary for optimal statistical parametric mapping (SPM)
analysis. For biochemical and immunohistochemical analyses
in WT mice groups of N = 6 mice at 6 and 18 months of
age were used without prior PET. A detailed overview of the
different groups of mice and all modalities is provided in
Table 1.
µPET
µPET Data Acquisition and Reconstruction
All mice were anesthetized with isoflurane (1.5%, delivered at
3.5 l/min) and placed in the aperture of the Siemens Inveon
DPET, as described previously (Rominger et al., 2010). For static
µPET recordings, anesthesia was maintained between tracer
injections until conclusion of the µPET acquisition, so as to
ensure comparable physiological conditions for the different
tracers.
[18F]-GE180 µPET: PS2APP mice and age-matched
C57Bl/6 controls were scanned in a full dynamic µPET
setting: Upon injection to a tail vein of 8.8 ± 2.3 MBq [18F]-
GE180 (in 150 µl saline), a 90 min emission recording was
initiated, followed by a 15 min transmission scan using a
rotating [57Co] point source. The 60-90 min static single frame
recordings were reconstructed based on prior knowledge from
our methodological investigation that this time window serves
best for standard-uptake-value-ratios (SUVR) quantitation
(Brendel et al., 2016).
[18F]-florbetaben µPET: Static single frame emission
recordings were made in the interval 30–60 min after injection to
a tail vein of 9.9 ± 1.7 MBq [18F]-florbetaben (in 150 µl saline),
followed by a 15 min transmission scan made using a rotating
[57Co] point source.
For all µPET recordings, reconstruction was performed with
four ordered-subset-expectation-maximization 3D iterations
and 32maximum-a-posteriori 3D iterations, a zoom factor of 1.0,
scatter-, attenuation- and decay-corrected, leading to a final voxel
dimension of 0.78 mm× 0.78 mm× 0.8 mm.
Image Co-Registration and Quantitative µPET Data
Analyses
Static datasets (30–60 or 60–90 min) were co-registered
to an MRI mouse atlas (Dorr et al., 2007) by a manual
rigid-body transformation (TXrigid) using the PMOD fusion
tool (V3.5, PMOD Technologies Ltd.), after blinding the
mouse identity to the reader. Accurate initial alignment
was verified by a second experienced reader. In the second
step, a reader-independent fine co-registration to tracer-
specific templates was performed. Templates were generated
by averaging all age specific PET scans for a single tracer,
with minor spatial re-registrations to guarantee optimal
overlapping of the two PET templates. Here, the initial
manual µPET-to-MRI atlas fusion images were normalized
by non-linear brain normalization (TXBN) to the tracer-
specific templates using the PMOD brain normalization
tool (equal modality; smoothing by 0.6 mm; nonlinear
warping; 16 iterations; frequency cutoff 3; regularization
1.0; no thresholding). The concatenation of TXrigid and
TXBN was then applied to µPET frames in the native space,
so as to obtain optimal resampling with a minimum of
interpolation.
Based on our previous experience, [18F]-GE180 and [18F]-
florbetaben data were scaled by different white matter reference
regions. In the case of [18F]-GE180 we used a 29 mm3 white
matter volume edited from the cerebellum and the brainstem
(Brendel et al., 2016), whereas for [18F]-florbetaben: we used
a 67 mm3 volume comprising pons, midbrain and hindbrain
parts of the subcortical white matter (Overhoff et al., 2016).
A main forebrain target volume-of-interest (VOI; 156 mm3)
comprising most of the frontal and parietal cortices as well as
the hippocampus and the thalamus was used for both tracers
to generate [18F]-GE180 and [18F]-florbetaben (SUVRCTX/WM),
which constitute the quantitative µPET endpoints.
SPM Analysis and Dice Coefficients
For both tracers, whole-brain voxel-wise comparisons of
white matter scaled images between age matched groups of
TG vs. WT mice (each N = 8) were performed by SPM
using SPM5 routines (Wellcome Department of Cognitive
TABLE 1 | Study overview for the different assessed modalities.
Mouse
Model
Age
(months)
[18F]-GE180
µPET (N)
[18F]-
florbetaben
µPET (N)
sTREM2/Aβ/
cytokines
(N)
Immuno-
histochemistry
(N)
PS2APP 5 8 8 6 6
8 8 8 4 4
13 8 8 8 8
16 8 8 7 7
C57Bl/6 5 8 8
6 6 6
8 8 8
13 8 8
16 8 8
18 6 6
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Neurology, London, UK). This analysis was implemented
in MATLAB (version 7.1), as adapted from Sawiak et al.
(2009) for mouse data. T-Score maps were all corrected for
multiple comparisons (FDR-corrected) at a significance level
of p < 0.05. Respective FDR-corrected T-score thresholds
were used for binarization (1 = significantly different to
WT/0 = not significantly different to WT) of the maps for
each tracer. For each age group, combined tracer distribution
maps were generated with four categories in each voxel:
0 = not significantly elevated for [18F]-GE180 and [18F]-
florbetaben; 1 = significantly elevated for [18F]-GE180 but
not [18F]-florbetaben; 2 = significantly elevated for [18F]-
florbetaben but not [18F]-GE180; 3 = significantly elevated for
both [18F]-GE180 and [18F]-florbetaben. These distributions
were consecutively compared relative to the whole brain volume
(%-occupancy), according to the distributions of each tracer
(stand-alone vs. combined voxels). Dice coefficients (Förster
et al., 2012) between non-binarized T-score maps of [18F]-
GE180 and [18F]-florbetaben were calculated for each time point
to assess the agreement of both tracer alterations as well with
regard to their regional magnitude.
Brain Extraction and Immunoblot Analysis
Frozen mouse cerebrum was cryo-pulverized in liquid nitrogen
and sequentially extracted in Tris-buffered saline (TBS)
followed by extraction with TBS-Triton (1%). In brief, 30 mg
cryo-pulverized samples of brain tissue were homogenized
in ice-cold TBS (10w/v) using a 26G needle and cleared by
ultracentrifugation (186,000× g, 1 h, 4◦C). The resulting pellet
was washed once with TBS, extracted with TBS-Triton (TBS-
T fraction) and lysate cleared again by ultracentrifugation
(186,000× g, 1 h, 4◦C).
For immunoblot analysis cryo-pulverized brains were
extracted in immunoprecipitation lysis buffer (25 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol)
and cleared by centrifugation (17,000× g, 30 min, 4◦C). Protein
concentrations were measured using the bicinchoninic acid
(BCA) method (Pierce). TREM2 was immunoprecipitated from
300 µg brain lysates using biotinylated anti-TREM2 (BAF1729;
R&D Systems) and Streptavidin sepharose (GE Healthcare)
overnight at 4◦C. Streptavidin sepharose was washed three times
with PBS and proteins eluted by boiling in 2× Laemmli sample
buffer supplemented with beta mercaptoethanol for 10 min at
95◦C.
Proteins were separated by SDS-PAGE and transferred
either onto polyvinylidene difluoride membranes (Hybond
P; Amersham Biosciences) or Nitrocellulose membranes
(GE Healthcare) and probed with rat anti-mouse TREM2
(clone 5F4; Xiang et al., 2016), rabbit anti-GFAP (Dako),
rabbit anti-IBA1 (Wako), rabbit anti-TSPO (Abcam)
and anti-GAPDH (Sigma). Bound antibodies were
visualized by corresponding HRP-conjugated secondary
antibodies using enhanced chemiluminescence technique
(Pierce). All buffers were supplemented with protease
inhibitors (Sigma).
Quantification of sTREM2 and Cytokines
by ELISA
sTREM2 and cytokines (MSD proinflammatory panel) were
quantified in TBS fractions from mouse brain using the
Mesoscale platform similar to previously described methods
(Kleinberger et al., 2014). The MSD proinflammatory panel
was performed according to manufacturer’s recommendations.
For sTREM2, streptavidin-coated 96-well small-spot plates were
blocked overnight at 4◦C in blocking buffer (3% bovine serum
albumin and 0.05% Tween-20 in PBS, pH 7.4). For the
detection of mouse sTREM2, plates were incubated for 1 h at
RT with 0.25 µg/ml biotinylated polyclonal goat anti-mouse
TREM2 capture antibody (R&D Systems; BAF1729) diluted in
sample diluent (1% bovine serum albumin and 0.05% Tween-20
in PBS, pH 7.4). Plates were washed subsequently for four
times with washing buffer (0.05% Tween-20 in PBS) and
incubated for 2 h at RT with samples diluted 1:2 in assay buffer
supplemented with protease inhibitors (Sigma). A recombinant
mouse TREM2 protein (Hölzel Diagnostika) was diluted in
assay buffer in a two-fold serial dilution and used for the
standard curve (Concentration range: 2000–31.25 pg/ml). Plates
were washed three times with washing buffer before incubation
for 1 h at RT with 1 µg/ml rat monoclonal anti-TREM2
antibody (R&D Systems, MAB1729) diluted in assay diluent.
After three additional washing steps, plates were incubated
with 0.5µg/ml SULFO-TAG-labeled anti-rat secondary antibody
(Meso Scale Discovery) and incubated for 1 h at RT. Lastly,
plates were washed three times with wash buffer followed and
developed by adding 1X Meso Scale Discovery Read buffer.
The light emission at 620 nm after electrochemical stimulation
was measured using the Meso Scale Discovery Sector Imager
2400 reader. Calculation of the concentration of sTREM2 was
performed with the MSD Discovery Workbench v4 software
(MSD).
Total Aβ ELISA
Total Aβ was quantified in TBS-Triton fractions similarly as
described above using biotinylated 2D8 as capture antibody,
mouse monoclonal 4G8 as detection antibody and SULF-TAG-
labeled anti-mouse secondary antibodies. A recombinant human
Aβ1–40 peptide (MSD) was diluted in assay buffer supplemented
with 6% fetal calf serum in a three-fold serial dilution and used
for the standard curve (Concentration range: 33–46 pg/ml).
Immunohistochemistry: Acquisition and
Image Analysis
Cerebral hemispheres intended for immunohistochemistry
(random side) were fixed by immersion in 4% paraformaldehyde
at 4◦C for 24 h. Two representative 50 µm thick slices per
animal were then cut in the axial plane using a vibratome (VT
1000 S, Leica, Wetzlar, Germany). Free-floating sections were
permeabilized with 2% Triton X-100 overnight and blocked with
10% normal goat serum. We obtained immunohistochemical
labeling of microglia using an Iba1 primary antibody
(dilution; Wako, 1:200), and the A-21244 secondary antibody
(Invitrogen, 1:500). The TSPO staining was obtained by
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incubation with anti-PBR antibody (Abcam, 1:300) and the
A-11034 secondary antibody (Invitrogen, 1:500). Fibrillary Aβ
plaques were stained with the fluorescent dye methoxy-X04
(0.01mgml−1 in phosphate-buffered saline at pH 7.4 for
15min) as described previously (Brendel et al., 2015b).
The unbound dye was removed by three washing steps
with PBS, and the slices were then mounted on microscope
slides with fluorescent mounting medium (Dako, Germany).
Images were acquired on an epi-fluorescence microscope
(Axio Imager.M2 with ApoTome.2, Jena, Zeiss, Germany).
Imaging of the whole slice was performed in tile scan mode,
which allows automatic stitching of an array of fields of
view. The area and number of plaques and microglia were
automatically counted using Imaris software (Imaris 7.6.5;
Bitplane, Zurich) in the entire cerebral cortex. These analyses
were performed by an operator who was blind to the µPET
results.
Statistics
Univariate analysis of variance (ANOVA) with Tukey post hoc
test was performed to compare values of different age groups
in PS2APP mice or to compare PS2APP mice against WT
littermates. Student’s t-test was used to compare results in groups
of young and aged WT. Normal distribution of data was verified
by the Kolmogorov-Smirnov test. For VOI-based correlation
analyses of µPET-derived estimates for microglial activation and
amyloidosis with sTREM2, Pearson’s coefficients of correlation
(R) were calculated. Multiple regression analysis was performed
to investigate the association of µPET-derived estimates for
microglial activation and amyloidosis with sTREM2 levels with
age as a fixed effect. The standardized regression coefficients (β)
are reported. IBM SPSS Statistics (version 22.0; SPSS, Chicago,
IL, USA) was used for all statistical tests. A threshold of
p < 0.05 was considered to be significant for rejection of
the null hypothesis. Standardized differences between PS2APP
and WT mice were computed for the defined time points in
PS2APP mice (under the assumption that measures in WT with
only two time-points are developing linearly during aging) and
divided by the standard deviation. For TBS Aβ levels at 5 and
8 months of age, a combined standard deviation was used as an
approximation for both time points as the singular results were
obviously distorted by the low standard deviation of mice aged
5 months.
RESULTS
Progressive Age-Dependent Increase of
sTREM2 Levels in the Brain of WT and
PS2APP Mice
Two independent studies have recently shown a significant
increase of CSF sTREM2 as a function of age (Piccio
et al., 2016; Suárez-Calvet et al., 2016b). Furthermore,
transgenic amyloid mouse models indicate an age dependent
increase of TREM2 mRNA expression in the brain
(Matarin et al., 2015). Hence, we first investigated the
levels of sTREM2 in post mortem brain homogenates
of PS2APP mice (Richards et al., 2003; Ozmen et al.,
2009) and WT littermates at different ages. ELISA based
quantification of sTREM2 in TBS extracts showed a significant
age-dependent increase of sTREM2 in the non-transgenic
C57BL/6 mice (Figure 1A; +19.2%; p < 0.05), which is in
line with an age-dependent increase of sTREM2 seen in
cognitively normal humans (Suárez-Calvet et al., 2016b).
Similarly, the TSPO µPET signal also showed a small but
significant increase in aged WT mice (Figure 1B; +4.0%;
p< 0.05).
In line with our previous µPET findings of increased fibrillar
amyloid deposition and glial activation in PS2APP mice with
age (Brendel et al., 2016), we observed a significant progressive
increase of sTREM2 (5 vs. 8 months: +82%, p < 0.05; 5 vs.
13 months: +165%, p< 0.001; 5 vs. 16 months: +211%, p< 0.001;
Figure 1A) which was far in excess of the age-dependent
increases in WT animals. Quantitation of the proinflammatory
cytokines Interleukin 1b, Interleukin 6 andKC/GRO (Interleukin
8 related protein) as well showed age-dependent increases in
PS2APP, however to a lesser extent compared to sTREM2.
In parallel, the TSPO µPET signal indicated the known
increase with age across the lifespan of PS2APPmice (Figure 1B).
Total Aβ advanced with age at similar extent when compared
to sTREM2 (5 vs. 8 months: +59%, p = n.s.; 5 vs. 13 months:
+165%, p < 0.001; 5 vs. 16 months: +223%, p < 0.001;
Figure 1C). Fibrillary plaque signal assessed by Aβ µPET showed
a delayed increase in the entire forebrain from 8months onwards
(Figure 1D).
Figure 2 illustrates the standardized differences of
biochemical and imaging measures for the PS2APP mouse
model during their life course. For this purpose, age dependent
differences between PS2APP and WT mice were computed
(under the assumption that measures in WT with only two
time-points are developing linearly during aging) and divided
by the standard deviation in PS2APP mice. Here standardized
differences of TSPO-PET and sTREM2 as well reached or
even exceeded the level of fibrillar Aβ deposition and total
Aβ. Standardized sTREM2 differences clearly exceeded those
of common cytokines at all time points. In summary, the
standardized timelines of sTREM2, TSPO-PET, Aβ-PET and
total Aβ were characterized by a high concordance.
Together, these results suggest that microglia activation, as
measured by TSPO µPET signal and sTREM2 measurement,
increase with normal aging, and this increase is strongly
augmented by amyloid pathology.
sTREM2 Is Highly Correlated with In Vivo
TSPO and Amyloidosis Biomarkers in
PS2APP Mice
Given the age-dependent increases of the several biomarkers,
we subsequently assessed the correlation between sTREM2 levels
and µPET results. The concentration of sTREM2 in the brain
showed a strong correlation with the TSPO µPET signal in
PS2APPmice (R = 0.89, p< 0.001; Figure 3A). The same analysis
in WT mice also indicated a positive correlation, although
less pronounced (R = 0.72, p < 0.05; Figure 3B). A strong
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FIGURE 1 | Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) increases in an age dependent manner in brains of PS2APP mice.
(A) Post mortem levels of sTREM2 were quantified by ELISA from forebrain tissue at indicated time-points (n = 4–8 mice per group). (B) Forebrain in vivo glial
activation assessed by 18-kDA translocator protein (TSPO) [18F]-GE180 µPET is presented as standard-uptake-value-ratios (SUVR) relative to white matter reference
tissue uptake (n = 8 mice per group). (C) Post mortem levels of total β-amyloid peptide (Aβ) were quantified by ELISA from forebrain tissue at indicated time-points
(n = 4–8 mice per group). (D) Forebrain in vivo amyloidosis assessed by [18F]-florbetaben µPET is presented as SUVR relative to white matter reference tissue uptake
(n = 8 mice per group). Data information: in (A–D), data are presented as mean ± SD. ∗significant differences in PS2APP mice vs. their 5 month old littermates
(∗p < 0.05; ∗∗p < 0.001); #significant differences in PS2APP mice vs. age-matched wild-type (WT; #p < 0.05; ##p < 0.001); ◦significant differences between young
and aged WT (◦p < 0.05). Analysis of variance (ANOVA) with Tukey post hoc applies for all. Please note that data of (B,D) were partially previously published (Brendel
et al., 2016).
positive correlation was as well observed between sTREM2 level
and fibrillar amyloidosis as assessed by Aβ µPET in PS2APP
(R = 0.92, p< 0.001; Figure 3C) but not inWTmice (Figure 3D).
FIGURE 2 | Standardized differences for biochemical and imaging
modalities during the life course of PS2APP mice. Data information:
standardized differences between PS2APP and WT mice were computed by
the delta divided by the standard deviation for all assessment points in
PS2APP. The development of measures in WT was assumed linear when no
direct comparison time-point was available.
The correlation between total Aβ and sTREM2 levels (R = 0.95;
p < 0.001) further supported the strong association between
sTREM2 and amyloidosis.
Next, we asked whether brain levels of sTREM2 are associated
with TSPO and Aβ µPET signals independently from age. To
this end, we performed a multiple regression analysis with
sTREM2 as an outcome variable, with TSPO µPET and Aβ
µPET as predictors, and with introduction of age as a covariate.
In this analysis, forebrain TSPO µPET signal was significantly
associated with sTREM2 (β = 0.40; p < 0.05), after adjusting for
age; forebrain TSPO µPET signal and age together accounted
for 84% of the variance in sTREM2 (F(2,22) = 61.5, p < 0.0001,
R2 = 0.85, R2Adjusted = 0.84). Forebrain Aβ µPET signal was also
significantly associated with sTREM2 (β = 0.53; p < 0.01), after
adjusting for age; forebrain Aβ µPET signal and age together
accounted for 86% of the variance in sTREM2 (F(2,22) = 77.5,
p< 0.0001, R2 = 0.88, R2Adjusted = 0.86).
In summary, we found a strong correlation of sTREM2 levels
and µPET findings of microglial activation and fibrillar
amyloidosis in PS2APP mice, a correlation that was highly
driven by age. Nonetheless, significant associations between
sTREM2 levels and uptake of both µPET tracers still remained,
even upon exclusion of age as a nuisance variable.
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FIGURE 3 | sTREM2 levels strongly correlate with dual tracer µPET in vivo measurements of TSPO and amyloidosis. (A,B) Correlation of post mortem
levels of sTREM2 in the forebrain with in vivo TSPO [18F]-GE180 µPET measurements in PS2APP and WT mice. (C,D) Correlation of post mortem levels of
sTREM2 in the forebrain with in vivo amyloid [18F]-florbetaben µPET measurements in PS2APP and WT mice. Data information: for all data Pearson’s coefficient of
correlation (R) was calculated together with the significance level using SPSS.
Widespread TSPO Activation Is Already
Established in Young PS2APP Mice
In the second step of image analysis, we used voxel-wise
dual tracer µPET results for a more detailed mapping of the
sequence of neuropathological alterations in the PS2APP mice.
In particular, we used SPM to test for spatial and temporal
relationships between neuroinflammation and amyloidosis as
measured by µPET in transgenic vs. age-matched WT mice.
Additional histochemical analyses were undertaken in order to
support the detection of a very early stage of fibrillar amyloid
deposition in the younger PS2APP mice, where detection
thresholds of µPET might be too low to detect the presence of
early pathology.
In this analysis, TSPO µPET revealed relevant microglial
activation (11% of the total brain volume; p < 0.05, FDR-
corrected) in PS2APP mice as young as 5 months, with main
foci in the frontal and parietal cortices, and also in the cerebellar
hemispheres (Figure 4A). At this early age, punctate fibrillar
amyloid depositions were detected by methoxy-X04 histology
in the frontal cortex of all PS2APP mice (Figure 5A), but
these were not sufficiently pronounced to impart a [18F]-
florbetaben Aβ µPET signal robust to correction for multiple
comparisons.
At 8 months of age, nearly one third of the brain volume in
PS2APP mice had increased TSPO µPET signal (32%; p < 0.05,
FDR-corrected; Figure 4B). Most of the regions with new TSPO
µPET specific binding arising between 5 and 8 months were
in the frontal, piriform and entorhinal cortical areas. 7% of
the brain volume had significantly elevated Aβ µPET signal at
8 months, with foci mainly in the frontal cortex and thalamus
(p < 0.05, FDR-corrected; Figure 4B), of which total 3% of the
total brain volume corresponded to regions with overlapping
TSPO and fibrillar Aβ increases relative to corresponding µPET
results in WT mice. Immunohistochemical analysis in the same
animals showed numerous small fibrillar plaques, generally
matching the regions with elevated amyloid µPET signal, and to
microscopic examination, surrounding IBA-1 and TSPO positive
cells (Figure 5B).
Together, these results indicate that microglial activation is
already established in large parts of the brain in young PS2APP
(5 and 8 months) mice, whereas fibrillar Aβ deposition is
less pronounced and restricted to specific areas. Inflammatory
processes clearly surround the establishment of early plaques, but
occur as well in areas without manifest fibrillar Aβ deposition
in young PS2APP mice, in which over-expressed Aβ is probably
present only in soluble form.
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FIGURE 4 | Glial activation and fibrillar amyloidosis progress regionally concerted during the life-cycle of PS2APP mice. (A–D) Voxel-wise regional
distribution of elevated in vivo radiotracer uptake in PS2APP mice compared to WT at all four different age stages. Increases in TSPO [18F]-GE180 µPET binding,
indicating glial activation (green), increases in amyloid [18F]-florbetaben µPET binding (red), and areas of overlapping increases for both radiotracers (blue) are
projected upon sagittal slices of an MRI mouse atlas. Data information: in (A–D) all voxels of the mouse brain were compared by a student’s t-test in SPM. All
significant differences exceeding a threshold of p < 0.05, including FDR-correction for multiple comparisons were binarized for each tracer.
TSPO Activity and Amyloidosis Progress
Concerted in Aging PS2APP Mice
Next, we mapped the regional progression of TSPO and Aβ
µPET signals in PS2APP mice aged more than 8 months in
order to discern the spatial relationship of the two biomarkers
later in life. We noted the enlargement of areas with overlapping
increases detected by dual tracer µPET in the forebrain, where
the total brain volume of concerted microglial activation and
amyloidosis increased from only 3% at 8 months to 24% at
13 months and 37% at 16 months (Figures 4B–D). Thus,
more than one third of the entire brain volume, notably in
the forebrain cortices, thalamus and hippocampus, manifested
concerted microglial activation and amyloidosis at 16 months
of age. This result was further strengthened by the increase in
dice similarity coefficients from initially low levels (1% similarity
at 5 months and 12% similarity at 8 months), progressing to
scores indicating very high agreement between brain voxels with
elevated TSPO and Aβ µPET binding in aged PS2APP mice
(63% similarity at 13 months and 69% similarity at 16 months
of age).
Immunohistochemical analyses confirmed theµPET findings
and indicated an age-dependent increase of fibrillary Aβ
plaques surrounded by numerous IBA-1 and TSPO positive
cells (Figures 5C,D). The WT mice themselves indicated an
age-dependent increase of IBA-1 positive cells (Figures 5E,F),
confirming the findings of a slight age-dependent elevation of
TSPO µPET signal together with increasing sTREM2 levels in
aged WT mice (Figures 1A, 3B).
We conclude from these voxel-wise dual tracer µPET
results that TSPO activity and fibrillar amyloidosis progress
in a concerted manner in PS2APP mice aged more than
1 year, ultimately co-expressing in most of the forebrain.
In contrast, WT mice showed only a subtle age-dependent
neuroinflammation, as revealed by IBA-1 positive cells by
immunohistochemistry. This result in WT mice confirmed the
significant increases in TSPO µPET signal between 6 and
18 months of age.
DISCUSSION
We present the first study employing post mortem assessment of
sTREM2 and Aβ in conjunction with dual-tracer small animal
µPET for TSPO and Aβ, aiming to reveal the spatial and
temporal relation between microglial activation and amyloidosis
during the life-course of a mouse AD model. The main
findings of the present study are: (1) sTREM2, TSPO and
amyloidosis progressively increase with age in the PS2APP
mouse model of AD; (2) sTREM2 levels, TSPO µPET and
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FIGURE 5 | Immunohistochemistry confirms µPET findings. (A–D) Immunohistochemistry in the frontal cortex of PS2APP and WT mice at different ages. TSPO
staining is depicted in green. IBA-1 positive cells are illustrated in red. Fibrillar Aβ plaques stained by methoxy-X04 are shown in blue. Scale bar in (A) indicates
100 µm. (E,F) Immunohistochemistry in the frontal cortex of WT mice at different ages. TSPO staining is depicted in green. IBA-1 positive cells are illustrated in red.
Please note that anti-TSPO recognizes an antigen in blood vessels a phenomenon that is well described in the literature. Therefore a higher zoom was used for a
proper visualization of increasing IBA-1 positive microglia in aged WT. Scale bar in (E) indicates 20 µm.
Aβ µPET uptake are all strongly associated with each other,
and still after exclusion of age; and (3) there is widespread
microgliosis in young PS2APP mice, along with early punctate
fibrillar Aβ deposition, which progresses to extensive overlap
of microglial activation and amyloidosis in the 16 month
old mice.
Our results show that sTREM2 levels and TSPO µPET
signal increase in parallel during normal aging of WT
mice, but that increase is more pronounced when there is
underlying amyloid pathology. These preclinical results are
consistent with findings previously described in humans in
a study showing an association of CSF sTREM2 levels with
increasing age both in cognitively normal subjects, and in
AD patients at different disease stages (Suárez-Calvet et al.,
2016b). Importantly, the increase of CSF sTREM2 as a function
of age was more pronounced in patients with underlying
AD pathology (even if they were in a preclinical stage)
than in cognitively normal subjects, a phenomenon which is
mirrored by the amyloid mouse model used in this study. It
is difficult to make a direct quantitative comparison of Aβ
deposition between human and mouse PET data. However, the
standardized differences of biochemical and imaging measures
for the PS2APP mouse model illustrated in Figure 2 show a
>5-fold in the double transgenic PS2APP mice for Aβ-PET,
as compared by standardized differences <2-fold in patients
with dominantly inherited AD (Bateman et al., 2012), which
gives a rough impression of the heavy amyloidosis in PS2APP
mice. Moreover standardized differences of TSPO-PET and
sTREM2 reached or even exceeded the level of fibrillar Aβ
deposition and total Aβ, underlining the parallel increase of
neuroinflammation and amyloidosis with age in the studied
mouse model.
In contrast, CSF sTREM2 samples of human dominantly
inherited AD increase below and temporally after Aβ, where
sTREM2 levels peak at symptom onset and drop again in
the later disease course (Suárez-Calvet et al., 2016a). In
sporadic AD the highest levels of CSF sTREM2 are as well
observed in early pre-symptomatic stages and likewise decrease
in manifest AD (Suárez-Calvet et al., 2016b). In opposite
our mouse model is characterized by a linear increase of
sTREM2 with advancing age. We attribute the current findings
to the fact that the mouse model—with ongoing amyloid
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deposition but very low levels of neuronal death—most likely
resembles the pre-symptomatic stage in humans. Noteworthy,
highest absolute deposition rates of Aβ by longitudinal PET
are observed at presymptomatic and MCI stages of sporadic
human AD (Villemagne et al., 2013; Brendel et al., 2015a).
Additionally CSF sTREM2 and Aβ only indicate an association
at the MCI stage of sporadic AD (Suárez-Calvet et al.,
2016b). Taken together sTREM2 might be specifically elevated
during active amyloid deposition in mice and humans. Such
considerations are in line with the time-dependent increase of
TREM2 mRNA in other Aβ transgenic mouse models (Matarin
et al., 2015; Wang et al., 2015), as well as an initial report of
increased plaque-associated TREM2 expression (Frank et al.,
2008).
Thus, our results demonstrate that amyloid pathology is
able to trigger microglial activation, irrespective of effect of
neurofibrillary tangles on neurodegeneration and neuronal
death per se. These results do not necessary contradict the
increasing evidence that TREM2 recognizes apoptotic neurons
and mediates their phagocytosis (Wang et al., 2015), and
likewise the fact that CSF sTREM2 are highly associated
with markers of neural injury (T-tau) and neurofibrillary
tangle neurodegeneration (P-tau; Heslegrave et al., 2016;
Piccio et al., 2016; Suárez-Calvet et al., 2016b). Instead,
these results speak to the possibility that both amyloid
pathology and neuronal death trigger microglial activation and
TREM2 production.
A key novelty of this study is due to the dual in vivo
imaging of neuroinflammation and fibrillar amyloidosis, which
preceded the assessment of TREM2 post mortem. The results of
TSPO imaging in vivo are strengthened by recent investigations
in transgenic AD mouse models: [11C]PBR28 showed a 27%
increase of brain uptake in 6 month old 5XFAD mice
compared to WT mice, confirmed by autoradiograpy and
immunohistochemistry (Mirzaei et al., 2016). Another study
in which the current TSPO tracer was successfully applied
revealed age-dependent increase of neuroinflammation in
APP/PS1dE9 mice, as confirmed by autoradiography ex vivo
and immunohistochemical in vitro assessments (Liu et al., 2015).
Additionally, our own validation study of the TSPO radioligand
proved that its kinetics favor robust and reproducible TSPO
imaging in PS2APP and WT mice, and gave high agreement
with post mortem immunohistochemistry findings (Brendel et al.,
2016).
In general, µPET can serve for longitudinal monitoring
ahead of terminal readouts in interventional designs, where
therapeutically induced alterations in biomarker associations
can be followed. Such studies addressing the effect of
genetic or therapeutic inhibition of microglial activation
(including TREM2) on amyloid deposition rates are the
focus of ongoing research (Birch et al., 2014; Tanzi, 2015).
Furthermore, knowing the individual baseline pathology levels
at therapy initiation, allows for more sensitive detection of
longitudinal biomarker changes in individual mice, as shown
in our recent anti-amyloid intervention µPET study (Brendel
et al., 2015c). Besides facilitating therapeutic advances, the
advantage of longitudinal assessments is also highlighted
by a recent study hypothesizing that different timing of
analyses accounts for discrepant findings of the effects of
TREM2 deficiency on Aβ accumulation (Wang et al., 2016).
By dual µPET longitudinal assessment, we can reveal dynamic
Aβ and TSPO phenotypic changes over time, which inform
the interpretation of terminal readouts, and may illuminate
pathogenic mechanisms.
Our regional µPET analyses allowed a detailed mapping
of TSPO activation and fibrillar amyloidosis in the mouse
brain over time. We find that young PS2APP mice already
manifest wide-spread microglial activation, even at an age when
fibrillary amyloid deposition is sparse, and only detectable by
highly sensitive histological methods, rather than by the less
sensitive [18F]-florbetaben µPET method, which yielded SUVR
not significantly elevated compared to common background
ratios observed in WT mice. This finding is in line with another
preclinical study that showed astrocytosis to precede fibrillar
amyloidosis in APPswe mice at 6 months of age (Rodriguez-
Vieitez et al., 2015). As total Aβ levels in our study were already
elevated at 5 months of age (Figure 1B), it seems likely that
soluble Aβ components, i.e., monomers and oligomers, and
the highly overexpressed APP itself may together trigger early
neuroinflammatory processes (Minter et al., 2015). Temporal
regional results for both radiotracers support this assumption,
as TSPO activity was elevated in quantitatively extensive brain
regions still lacking fibrillar amyloid plaques at 5 and 8 months
of age (Figure 6).
FIGURE 6 | Quantitative progression of glial activation and fibrillar
amyloidosis during the life-cycle of PS2APP mice. (A–D) Percentage (%)
of brain voxels relative to the whole brain in which binding of either
[18F]-GE180 (green) or [18F]-florbetaben (FBB, red) or both tracers (blue) in
groups of PS2APP mice exceeded that in WT mice at 5, 8, 13 or 16 months
of age. Data information: arrows between boxes indicate the propagation of
changing volume percentages for the two markers between groups of
increasing age. Inward and outward arrows indicate the amount volume
percentage of newly presenting/disappearing voxels for the markers at each
specific age group. Thin arrows indicate 1–5% volume changes, medium
arrows 5–10% changes, and thick arrow show changes exceeding 10%
volumes. In (A–D) all voxels of the mouse brain were compared by a student’s
t-test in statistical parametric mapping (SPM). All significant differences
exceeding a threshold of p < 0.05, including FDR-correction for multiple
comparisons were binarized for each tracer.
Frontiers in Aging Neuroscience | www.frontiersin.org 10 January 2017 | Volume 9 | Article 8
Brendel et al. TREM2 and Microglia in the PS2APP Mouse Model
The study has some limitations. First, we used µPET
data derived from a cross-sectional study, since a true
longitudinal design would not easily have afforded longitudinal
sTREM2 assays; we expect that repeated CSF sampling would
have greatly increased dropout rates. Overall, we feel that
biases possibly arising from the cross-sectional design are
well balanced by the use of adequately powered group sizes.
In the immunohistochemistry end readout we focused on
well-established IBA-1 staining and robust TSPO staining.
However, vessel staining by TSPO antibodies still hampering
quantitation, and may imperil our conclusions about group
differences. We consider it unlikely that TSPO vessel staining
contributes importantly to the TSPOµPET signal, since 6 month
old WT mice with heavy vessel staining had significantly
lower [18F]-GE180 SUVR when compared to PS2APP mice
at 5 months. Thus, we consider the vessel staining in
immunohistochemistry as likely to be unspecific. Increased levels
of sTREM2 in the used double transgenic mouse model may
be influenced by altered γ-secretase activity (Wunderlich et al.,
2013). Although we deem strong effects to be unlikely, it will
be valuable to confirm current findings in AD models without
overexpression of PSEN or APP.
CONCLUSION
In conclusion, PS2APP mice show a strong correlation between
sTREM2 levels, microglial activation and amyloidosis, indicating
that sTREM2 serves as a biomarker for microglial activity, which
is, in turn, highly driven by the heavy amyloidosis in this mouse
model. Our data suggest that sTREM2may increase during active
amyloid deposition and that the inflammatory response in this
mouse model possibly reflects a specific stage of AD, most likely
the preclinical stage, characterized by high amyloid accumulation
rates. Regional data indicate widespread microglial activation
in young PS2APP mice, and concerted progression of amyloid
pathology and TSPO elevation during their life course. Causal
relationships need to be tested in longitudinal multi-tracerµPET
studies with interventions targeting specific aspects of AD-like
pathology.
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